Pinealon vs Semax

Origin and structure

Pinealon is a synthetic tripeptide (Glu-Asp-Arg, EDR) developed at the St Petersburg Institute of Bioregulation and Gerontology as part of Vladimir Khavinson's short-peptide "cytomedine" family, the same programme that produced Epitalon and Thymalin.

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro), an analogue of the ACTH(4-10) fragment with a stabilising Pro-Gly-Pro tail, developed independently in the 1980s by Ivan Ashmarin's group at Moscow State University. It comes from an entirely different research lineage to the Khavinson cytomedine programme, rooted instead in neuroendocrinology of dissociated (non-hormonal) ACTH-fragment activity.

Mechanism

Pinealon's proposed mechanism follows the Khavinson-family gene-regulatory model: the tripeptide is hypothesised to reach the nucleus and bind DNA promoter motifs favouring antioxidant-defence and antiapoptotic genes in neuronal lineages, reducing reactive-oxygen-species accumulation and caspase-3 activation under oxidative and hypoxic stress.

Semax's best-supported mechanism is upregulation of brain-derived neurotrophic factor (BDNF) and NGF expression in hippocampus and cortex (Dolotov et al. 2006), alongside modulation of dopaminergic and serotonergic turnover (Eremin et al. 2005) and direct neuroprotection in cerebral-ischaemia models. Unlike Pinealon, Semax was specifically engineered to strip out ACTH's endocrine (corticotropic) activity while retaining neurotropic effects — it does not raise cortisol or act at classical corticotropin receptors.

Evidence base

Both peptides rest on a research base concentrated within their originating Russian institutions, with limited independent international replication. Pinealon's literature is smaller and centres on rodent hypoxia, oxidative-stress and cognitive-preservation studies (Arutjunyan et al. 2012; Kozina et al. 2014). Semax has a somewhat larger and more internationally published mechanistic literature — particularly on BDNF/TrkB signalling — plus a multi-decade Russian clinical record in acute ischaemic stroke (Gusev et al. 2008), where it holds state medicine registration.

Neither compound has been through a randomised controlled trial meeting MHRA, EMA or FDA standards. Semax's clinical literature, while larger in volume, is predominantly open-label or comparator-controlled rather than placebo-controlled in the modern sense.

Research positioning

Pinealon is positioned within the Khavinson catalogue as the neural-tissue-selective bioregulator, complementing Epitalon's broader systemic-ageing remit. Semax is positioned as a stroke-rehabilitation and cognitive-disorder agent with a distinct, non-hormonal mechanism, and has separately attracted informal interest as a nootropic — a use case quite different from the medically supervised contexts in which its Russian clinical literature was generated. The two are often mentioned together by researchers exploring Russian-developed neurotropic peptides, but their evidentiary and mechanistic foundations should not be conflated.

Summary table

For the full evidence base, see the individual pages: Read the full Pinealon entry and Read the full Semax entry.